Adverum Biotechnologies Statistics
Share Statistics
Adverum Biotechnologies has 20.80M shares outstanding. The number of shares has increased by -79.41% in one year.
| Shares Outstanding | 20.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 12.25M |
| Failed to Deliver (FTD) Shares | 1.30K |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 1.60M, so 7.71% of the outstanding shares have been sold short.
| Short Interest | 1.60M |
| Short % of Shares Out | 7.71% |
| Short % of Float | 13.1% |
| Short Ratio (days to cover) | 7.41 |
Valuation Ratios
The PE ratio is -0.65 and the forward PE ratio is -1.48.
| PE Ratio | -0.65 |
| Forward PE | -1.48 |
| PS Ratio | 21.09 |
| Forward PS | 14.7 |
| PB Ratio | 0.91 |
| P/FCF Ratio | -0.83 |
| PEG Ratio | n/a |
Enterprise Valuation
Adverum Biotechnologies Inc. has an Enterprise Value (EV) of 75.96M.
| EV / Earnings | -0.65 |
| EV / Sales | 21.1 |
| EV / EBITDA | -0.67 |
| EV / EBIT | -0.61 |
| EV / FCF | -0.83 |
Financial Position
The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.13 |
| Quick Ratio | 4.13 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 11.09 |
| Cash Flow / Debt | -8.73 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.4% and return on capital (ROIC) is -77.39%.
| Return on Equity (ROE) | -1.4% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | -77.39% |
| Revenue Per Employee | 29.75K |
| Profits Per Employee | -968.31K |
| Employee Count | 121 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.08M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -33.99% in the last 52 weeks. The beta is 1.01, so Adverum Biotechnologies 's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -33.99% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 8.84 |
| Relative Strength Index (RSI) | 31.66 |
| Average Volume (20 Days) | 228.15K |
Income Statement
In the last 12 months, Adverum Biotechnologies had revenue of $3.60M and earned -$117.17M in profits. Earnings per share was $-11.62.
| Revenue | 3.60M |
| Gross Profit | -2.04M |
| Operating Income | -123.79M |
| Net Income | -117.17M |
| EBITDA | -112.60M |
| EBIT | -123.79M |
| Earnings Per Share (EPS) | -11.62 |
Balance Sheet
The company has $75.00M in cash and $75.04M in debt, giving a net cash position of -$36.00K.
| Cash & Cash Equivalents | 75.00M |
| Total Debt | 75.04M |
| Net Cash | -36.00K |
| Retained Earnings | -919.78M |
| Total Assets | 234.38M |
| Working Capital | 133.42M |
Cash Flow
In the last 12 months, operating cash flow was -$90.90M and capital expenditures -$808.00K, giving a free cash flow of -$91.71M.
| Operating Cash Flow | -90.90M |
| Capital Expenditures | -808.00K |
| Free Cash Flow | -91.71M |
| FCF Per Share | -9.1 |
Margins
Gross margin is -56.78%, with operating and profit margins of -3.44K% and -3.25K%.
| Gross Margin | -56.78% |
| Operating Margin | -3.44K% |
| Pretax Margin | -3.28K% |
| Profit Margin | -3.25K% |
| EBITDA Margin | -3.13K% |
| EBIT Margin | -3.44K% |
| FCF Margin | -2.55K% |
Dividends & Yields
ADVM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -215.99% |
| FCF Yield | -81.94% |
Analyst Forecast
The average price target for ADVM is $27.5, which is 411.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.5 |
| Price Target Difference | 411.2% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 21, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Mar 21, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -5.84 |
| Piotroski F-Score | 3 |